ID: ALA2434997

Max Phase: Preclinical

Molecular Formula: C19H16N4O

Molecular Weight: 316.36

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN(C)c1cc[n+]([C-](C=C(C#N)C#N)C(=O)c2ccccc2)cc1

Standard InChI:  InChI=1S/C19H16N4O/c1-22(2)17-8-10-23(11-9-17)18(12-15(13-20)14-21)19(24)16-6-4-3-5-7-16/h3-12H,1-2H3

Standard InChI Key:  SHIOBPJQDMLVCL-UHFFFAOYSA-N

Associated Targets(Human)

Protein farnesyltransferase 3470 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 316.36Molecular Weight (Monoisotopic): 316.1324AlogP: 2.28#Rotatable Bonds: 5
Polar Surface Area: 71.77Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.85CX Basic pKa: CX LogP: -1.44CX LogD: -1.44
Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.37Np Likeness Score: -0.63

References

1. Abuhaie CM, Ghinet A, Farce A, Dubois J, Rigo B, Bîcu E..  (2013)  Synthesis and biological evaluation of a new series of N-ylides as protein farnesyltransferase inhibitors.,  23  (21): [PMID:24054122] [10.1016/j.bmcl.2013.08.088]

Source